UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
NEW YORK, Dec. 16, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) securities between February 10, 2014 and November 9, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/alexion-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Alexion made false and/or misleading statements and/or failed to disclose: (1) that the Company employed improper sales practices with respect to its product Soliris; (2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times.
On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. The Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this news was announced, shares of Alexion fell in value, causing investors harm.
If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/alexion-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
